ContractProteostasis Therapeutics, Inc. • June 18th, 2015 • Pharmaceutical preparations • Massachusetts
THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE SECURITIES ACT, OR (B) THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS.
CONFIDENTIAL June 13, 2014 Dr. Markus Haeberlein Dear Markus:Proteostasis Therapeutics, Inc. • June 18th, 2015 • Pharmaceutical preparations • Massachusetts
The Board of Directors and I have recently reviewed the terms and conditions of your employment and are please to provide this letter agreement effective February 1, 2014 covering your expanded role as Senior Vice President, Chief Scientific Officer, for Proteostasis Therapeutics, Inc. (“Proteostasis” or the “Company”). This letter further amends, restates, and supersedes in its entirety that certain amended and restated letter agreement dated February 28, 2013, and that certain employment offer letter dated May 10, 2012, between you and the Company.
ContractCollaboration and License Agreement • June 18th, 2015 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations • New York
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • June 18th, 2015 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This License Agreement (this “Agreement”) is entered into as of the Amendment Effective Date (as defined below), by and between Proteostasis Therapeutics, Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 200 Technology Square, 4th Floor, Cambridge, MA 02139 (“Licensee”) and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Holyoke Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”).
Indemnification AgreementIndemnification Agreement • June 18th, 2015 • Proteostasis Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement made effective as of [DATE] (the “Agreement”), by and between Proteostasis Therapeutics, Inc., a Delaware corporation (the “Corporation,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Corporation) and [DIRECTOR OR OFFICER NAME] (the “Indemnitee”):
